Public procurement notice: Voluntary Ex Ante Transparency Notice
Published: 2019-04-19
Buyer: Sykehusinnkjøp HF
Country: NO
Contract type: Supplies
Procedure: Contract award without prior publication
CPV classification: 33600000: Pharmaceutical products
Estimated value: 521700000 NOK
Award criteria: Lowest price

Technical requirements: Sykehusinnkjøp HF, Medicines Division (LIS) is collecting tenders for medicines that are used by the Health Trusts. LIS has previously published and implemented an open tender competition regarding bone marrow cancer and other indications (“LIS 1807ibenmargskreft benmargskreft/øvrige indikasjoner"). The competition included the active ingredients that were in accordance with the tender documentation, annex 3 — the Active Ingredients List.
LIS has examined the market situation and is of the opinion that there are no other suppliers than the current suppliers that can deliver the products in the contract period. In addition, the situation that has occurred is not the Contracting Authority's fault, nor something that the Contracting Authority could foresee. LIS therefore believes that there is statutory basis,for entering these contracts Cf. the Public Procurement Regulations § 13-4 first section, letter b,) No 3.
Based on this information, LIS intends to extend the contract between the Regional Health Authorities (the Contracting Authorities) and mentioned suppliers. This means that 5 new Framework Agreements shall be established with new contract periods and with the same contractual terms as determined in the previous contract period. Attached to the tender notice is an overview of preparations, suppliers and contract periods.
Unless LIS receives objections within the waiting period of 10 calendar days, a contract shall be entered.
Sykehusinnkjøp HF, Medicines Division (LIS) is collecting tenders for medicines that are used by the Health Trusts. LIS has previously published and implemented an open tender competition regarding bone marrow cancer and other indications (“LIS 1807i benmargskreft/øvrige indikasjoner"). The contest was for the active ingredients that were in accordance with the tender documentation, annex 3 Active Ingredients List.
LIS has examined the market situation and is of the opinion that there are no other suppliers than the current suppliers that can deliver the products in the contract period. In addition, the situation that has occurred is not the Contracting Authority's fault, nor something that the Contracting Authority could foresee. LIS therefore believes that there are grounds for entering the contracts Cf. the Public Procurement Regulations § 13-4 first section, letter b,) No 3.
Based on this information, LIS intends to extend the contract between the Regional Health Authorities (the Contracting Authorities) and mentioned suppliers. This means that 5 new Framework Agreements shall be established with new contract periods and with the same contractual terms as determined in the previous contract period. Attached to the tender notice is an overview of preparations, suppliers and contract periods.
Unless LIS receives objections within the waiting period of 10 calendar days, a contract shall be entered.


Winner: Janssen-Cilag AS
Award value: 521700000